Investors who got shares in Anondita Medicare’s IPO are celebrating a massive jump in value, turning a modest investment into a small fortune.
Stunning price rise after listing
The stock debuted on the NSE SME platform at ₹275.50, almost double the issue price of ₹145. Within a few trading days it hit the 5% upper‑circuit limit repeatedly, climbing to ₹867. That’s a nearly 500% gain from the IPO price.
What a tiny retail allotment could have earned
If an investor received the minimum retail allocation – two lots or 2,000 shares – and held onto them, the investment would be worth about ₹1.73 million today, up from roughly ₹16.5 thousand at the IPO. In other words, the stake would have grown by roughly ₹1.7 million in under four months.
Massive demand for the IPO
The IPO was heavily oversubscribed:
- Total subscription: 301 times the offer
- Retail (non‑institutional) quota: 531.82 times
- Qualified Institutional Buyers (QIB): 153.03 times
- Overall bids received: 95,47,28,000 shares against 31,73,000 shares on offer
The issue raised ₹69.5 crore from a fresh issue of 0.48 million shares priced between ₹137 and ₹145.
About Anondita Medicare
Founded in March 2024, Anondita Medicare makes flavored male condoms under the brand “COBRA.” The company can produce 562 million condoms a year from its Noida plant and exports to Southeast Asia, Africa, and the Middle East.
Why the stock stands out in 2025
Among the 260 SME IPOs that have listed so far this year, Anondita Medicare is one of the top performers. While many IPOs have struggled—about half of all 366 issues across main board and SME markets trade below their issue price—Anondita’s share price surge makes it a rare success story.
Key takeaways for investors
- Strong demand can push SME IPO prices far above the issue price.
- Retail investors who secure even a small allotment can see outsized returns if the stock gains momentum.
- Company fundamentals (production capacity, export markets) help support investor confidence.
Remember, this is perspective, not a prediction. Do your own research or consult a certified expert before making any investment decisions.